Date: October 28, 2021

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization, Part 4 – Biological Products

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 mRNA Vaccine COMIRNATY™ (Pfizer-BioNTech)

- **Doses and Schedule:**
  - The dose and schedule for the booster dose has been added.
  - Footnote G has been added to indicate that Health Canada approval for Pfizer (COMIRNATY™) booster dose indications is expected for those 16 years of age and older. A decision to use the vaccine for booster dose for those aged 12-15 years should consider the individual benefits and risks.
  - Footnote H has been updated to indicate that while the minimum interval between completion of the primary series and the booster dose is 28 days, this would apply to a minority of individuals for practical reasons, with consideration of the individual benefits and risks, and should not be used as a routine interval.

- **Booster Doses:**
  - The populations for whom a booster dose of a COVID-19 mRNA vaccine is recommended have been updated.

  Please remove page numbers: 1-6 dated October 15, 2021
  Please add new page numbers: 1-6 dated October 28, 2021

COVID-19 mRNA Vaccine SPIKEVAX™ (Moderna)

- **Doses and Schedule:**
  - The dose and schedule for the booster dose has been added. **Note:** for certain populations, the booster dose for the Moderna COVID-19 mRNA vaccine is 0.25 mL, which is half of the volume of a primary series dose.
  - Footnote G has been added to indicate that Health Canada approval for Moderna (SPIKEVAX™) booster dose indications is expected for those 18 years of age and older. A decision to use the vaccine for booster dose for those aged 12-17 years should consider the individual benefits and risks.
Footnote H has been updated to indicate that while the minimum interval between completion of the primary series and the booster dose is 28 days, this would apply to a minority of individuals for practical reasons, with consideration of individual benefits and risks, and should not be used as a routine interval.

- **Booster Doses:**
  - The populations for whom a booster dose of a COVID-19 mRNA vaccine is recommended have been updated.

Please remove page numbers: 1-5 dated October 15, 2021
Please add new page numbers: 1-6 dated October 28, 2021

**COVID-19 Vaccine VAXZEVRIA™/COVISHIELD (AstraZeneca/Verity Pharmaceuticals)**

- **Booster Doses:**
  - The populations for whom a booster dose of a COVID-19 mRNA vaccine is recommended have been updated.
  - Footnote A has been updated to indicate that while the minimum interval between completion of the primary series and the booster dose is 28 days, this would apply to a minority of individuals for practical reasons, with consideration of individual benefits and risks, and should not be used as a routine interval.

Please remove page numbers: 1-5 dated October 15, 2021
Please add new page numbers: 1-5 dated October 28, 2021

**COVID-19 Vaccine (Ad26.COV2.S [recombinant]) (Janssen Inc.)**

- **Booster Doses:**
  - The populations for whom a booster dose of a COVID-19 mRNA vaccine is recommended have been updated.
  - Footnote C has been updated to indicate that while the minimum interval between completion of the primary series and the booster dose is 28 days, this would apply to a minority of individuals for practical reasons, with consideration of individual benefits and risks, and should not be used as a routine interval.

- **Contraindications:**
  - History of capillary leak syndrome has been added.

Please remove page numbers: 1-4 dated October 15, 2021
Please add new page numbers: 1-5 dated October 28, 2021
If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:

Provincial Health Officer
Dr. Bonnie Henry

Dr. Reka Gustafson
Vice President, Public Health & Wellness, PHSA & Deputy Provincial Health Officer

Deputy Provincial Health Officer
Dr. Martin Lavoie

BC Ministry of Health, Population & Public Health Division:

Brian Sagar
Senior Director Communicable Disease, Population and Public Health Division

Bernard Achampong
Executive Director, Public Health, Planning and Prevention, Population and Public Health Division